{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:13:00Z","timestamp":1789409580336,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["15FTF25890062"],"award-info":[{"award-number":["15FTF25890062"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","award":["HL-064750"],"award-info":[{"award-number":["HL-064750"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","award":["K08-HL-123744"],"award-info":[{"award-number":["K08-HL-123744"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","award":["HL-166606"],"award-info":[{"award-number":["HL-166606"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular and Cellular Cardiology Plus"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jmccpl.2025.100296","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:31:21Z","timestamp":1744165881000},"page":"100296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["SGLT2 inhibitor upregulates myocardial genes for oxidative phosphorylation and fatty acid metabolism in G\u03b1q-mice"],"prefix":"10.1016","volume":"12","author":[{"given":"Jordan M.","family":"Chambers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Croteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C.","family":"Gower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Panagia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Baka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuzhong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Luptak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson S.","family":"Colucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmccpl.2025.100296_bb0005","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.119.040551","article-title":"Unlocking the secrets of mitochondria in the cardiovascular system: path to a cure in heart failure-a report from the 2018 national heart, lung, and blood institute workshop","volume":"140","author":"Tian","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0010","series-title":"Heart failure: A companion to Braunwald\u2019s heart disease","first-page":"181","article-title":"Oxidative stress in heart failure","author":"Sawyer","year":"2004"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0015","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/01.HYP.0000254415.31362.a7","article-title":"Role of oxidative stress in cardiac hypertrophy and remodeling","volume":"49","author":"Takimoto","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0020","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0025","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0030","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jacbts.2017.07.003","article-title":"Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure","volume":"2","author":"Byrne","year":"2017","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0035","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0040","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0045","article-title":"Direct cardiac actions of sodium-glucose cotransporter 2 inhibition improve mitochondrial function and attenuate oxidative stress in pressure overload-induced heart failure","volume":"9","author":"Li","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0050","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0055","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","article-title":"SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism","volume":"20","author":"Packer","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0060","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019995","article-title":"Effects of sodium-glucose linked transporter 2 inhibition with ertugliflozin on mitochondrial function, energetics, and metabolic gene expression in the presence and absence of diabetes mellitus in mice","volume":"10","author":"Croteau","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0065","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1126\/science.280.5363.574","article-title":"Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy","volume":"280","author":"Akhter","year":"1998","journal-title":"Science"},{"issue":"1\u20132","key":"10.1016\/j.jmccpl.2025.100296_bb0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1050-1738(99)00004-3","article-title":"Gq signaling in cardiac adaptation and maladaptation","volume":"9","author":"Dorn","year":"1999","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0075","doi-asserted-by":"crossref","first-page":"10140","DOI":"10.1073\/pnas.95.17.10140","article-title":"Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure","volume":"95","author":"Adams","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0080","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCHEARTFAILURE.109.864785","article-title":"Cardiac-specific overexpression of catalase identifies hydrogen peroxide-dependent and -independent phases of myocardial remodeling and prevents the progression to overt heart failure in G(alpha)q-overexpressing transgenic mice","volume":"3","author":"Qin","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0085","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1161\/CIRCRESAHA.116.304682","article-title":"Mitochondrial reprogramming induced by CaMKIIdelta mediates hypertrophy decompensation","volume":"116","author":"Westenbrink","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0090","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCRESAHA.110.232306","article-title":"Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure","volume":"108","author":"Dai","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0095","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1093\/eurheartj\/ehab420","article-title":"Effects of canagliflozin on human myocardial redox signalling: clinical implications","volume":"42","author":"Kondo","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0100","first-page":"5","article-title":"Mitochondrial reactive oxygen species mediate cardiac structural, functional, and mitochondrial consequences of diet-induced metabolic heart disease","author":"Sverdlov","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0105","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1089\/ars.2018.7707","article-title":"Energetic dysfunction is mediated by mitochondrial reactive oxygen species and precedes structural remodeling in metabolic heart disease","volume":"31","author":"Luptak","year":"2019","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0110","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.yjmcc.2018.01.017","article-title":"Decreased ATP production and myocardial contractile reserve in metabolic heart disease","volume":"116","author":"Luptak","year":"2018","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0115","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0120","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.cellsig.2014.01.009","article-title":"A new non-canonical pathway of Galpha(q) protein regulating mitochondrial dynamics and bioenergetics","volume":"26","author":"Beninca","year":"2014","journal-title":"Cell Signal"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0125","article-title":"SGLT2 inhibitors activate pantothenate kinase in the human heart","author":"Forelli","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0130","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","article-title":"Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction","volume":"21","author":"Yurista","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0135","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac energy metabolism in heart failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.jmccpl.2025.100296_bb0140","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1021\/jm200049r","article-title":"Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors","volume":"54","author":"Mascitti","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.jmccpl.2025.100296_bb2005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","article-title":"Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potetntial off-target effects","volume":"167","author":"Dyck","year":"2022","journal-title":"J Mol Cell Cardiol"}],"container-title":["Journal of Molecular and Cellular Cardiology Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772976125000157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772976125000157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:42:07Z","timestamp":1762648927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772976125000157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":29,"alternative-id":["S2772976125000157"],"URL":"https:\/\/doi.org\/10.1016\/j.jmccpl.2025.100296","relation":{},"ISSN":["2772-9761"],"issn-type":[{"value":"2772-9761","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 inhibitor upregulates myocardial genes for oxidative phosphorylation and fatty acid metabolism in G\u03b1q-mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular and Cellular Cardiology Plus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmccpl.2025.100296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100296"}}